Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Epitomee Medical Ltd specializes in developing innovative medical devices aimed at obesity management, particularly through its proprietary gastric balloon technology. The company operates primarily in Israel but has ambitions to expand into European and North American markets, leveraging its unique product offerings to address the growing global obesity epidemic.
Epitomee Medical generates revenue primarily through the sale of its gastric balloons, which are designed for non-invasive weight loss procedures. The company has a competitive advantage due to its patented technology that offers a less invasive alternative to traditional bariatric surgery, allowing for higher patient acceptance and lower operational costs for clinics.
Regulatory approvals for new products, particularly in key markets like the EU and North America
Partnerships with healthcare providers and clinics to expand distribution
Clinical trial results demonstrating the efficacy and safety of its products
Market trends in obesity treatment and healthcare spending
Regulatory changes that could impact the approval process for medical devices
Technological disruption from competitors developing alternative obesity treatments
Emergence of new competitors in the non-invasive obesity treatment space
Price competition from established medical device manufacturers
High operational losses leading to potential liquidity issues if funding is not secured
Dependence on external financing for R&D and operational expenses
moderate - The demand for medical devices can be sensitive to economic cycles, as healthcare spending tends to fluctuate with consumer confidence and disposable income.
Interest rates can affect Epitomee Medical's ability to finance operations and R&D, impacting its valuation as higher rates may lead to increased borrowing costs.
minimal - The company's low debt levels (Debt/Equity of 0.21) suggest limited exposure to credit conditions.
growth - Investors looking for high-risk, high-reward opportunities in the medical device sector may find Epitomee appealing due to its innovative product pipeline.
high - Given the company's current operational losses and reliance on future product approvals, the stock is likely to exhibit significant volatility.
